UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 10:15-10:55 a.m. ET.
The webcast of the fireside chat will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…
BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…
New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…
DELRAY BEACH, Fla., Feb. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Digital X-ray Market…
WINSTON-SALEM, N.C., Feb. 2, 2026 /PRNewswire/ -- mPATH® Health, a digital health company focused on improving…
WOBURN, Mass., Feb. 2, 2026 /PRNewswire/ -- TeachTown, a leading provider of special education curriculum for…